Novo Unveils Sustainable Growth, 2030 Targets at Capital Markets Day

05:36 AM EDT, 09/21/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) is targeting sustainable growth, including revenue to grow in line with industry peers, through 2030. The Danish pharmaceutical giant said Monday its same-day capital markets event will also detail its plans to scale its oral GLP-1 capacity to cover 10x more people with obesity by 2030 and serve at least 60 million patients globally. Novo also plans to launch more than five multi-blockbuster products by 2030 and generate over 150 billion Danish kroner in pipeline sales in 2035. Additionally, it targets at least five phase 3 programs in obesity and diabetes, as well as in other therapy areas.